SHAREHOLDER ALERT: Brower Piven Announces the Investigation of Zalicus, Inc. over the Proposed Merger with Epirus Biopharmace...
April 16 2014 - 3:50PM
Business Wire
The securities litigation law firm of Brower Piven, A
Professional Corporation, has commenced an investigation into
possible breaches of fiduciary duty to current shareholders of
Zalicus, Inc. (“Zalicus” or the “Company”) (NasdaqCM: ZLCS) and
other violations of state law by the board of directors of Zalicus
relating to the proposed merger of the Company with Epirus
Biopharmraceuticals, Inc. (“Epirus”).
Under the terms of the transaction, the percentage of the
combined company that Zalicus shareholders will own as of the
closing of the merger is subject to an adjustment at closing based
on the level of Zalicus net cash at closing. If the merger were to
close today, the stockholders of Zalicus would own only 14% of the
combined company.
The firm’s investigation seeks to determine, among other things,
whether the Company’s board of directors breached their fiduciary
duties by failing to maximize shareholder value before agreeing to
enter into this transaction, and whether Epirus is underpaying for
Zalicus shares.
If you currently own common stock of Zalicus and would like to
learn more about the investigation being conducted by Brower Piven,
without cost or obligation to you, click here:
http://www.browerpiven.com/currentinvestigations.html.
You may also request more information by contacting Brower Piven
either by email at hoffman@browerpiven.com or by telephone at (410)
415-6616. Attorneys at Brower Piven together have more than a
century of experience litigating securities and other class action
cases.
Brower Piven, A Professional Corporation1925 Old Valley
RoadStevenson, Maryland 21153Charles J. Piven,
410-415-6616hoffman@browerpiven.com
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Historical Stock Chart
From Apr 2024 to May 2024
EPIRUS Biopharmaceuticals (CE) (USOTC:EPRSQ)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about EPIRUS Biopharmaceuticals Inc (CE) (OTCMarkets): 0 recent articles
More Zalicus Inc. (MM) News Articles